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Abstract
The tuberculin skin test (TST) is widely used in TB clinics to aid Mycobacterium tuberculosis (M.tb) diagnosis, but the
definition and the significance of a positive test in very young children is still unclear. This study compared the TST in
Gambian children at 4K months of age who either received BCG vaccination at birth (Group 1) or were BCG naı ¨ve (Group 2)
in order to examine the role of BCG vaccination and/or exposure to environmental mycobacteria in TST reactivity at this age.
Nearly half of the BCG vaccinated children had a positive TST ($5 mm) whereas all the BCG naı ¨ve children were non-
reactive, confirming that recent BCG vaccination affects TST reactivity. The BCG naı ¨ve children demonstrated in vitro PPD
responses in peripheral blood in the absence of TST reactivity, supporting exposure to and priming by environmental
mycobacterial antigens. Group 2 were then vaccinated at 4K months of age and a repeat TST was performed at 20–28
months of age. Positive reactivity ($5 mm) was evident in 11.1% and 12.5% infants from Group 1 and Group 2 respectively
suggesting that the timing of BCG vaccination had little effect by this age. We further assessed for immune correlates in
peripheral blood at 4K months of age. Mycobacterial specific IFNc responses were greater in TST responders than in non-
responders, although the size of induration did not correlate with IFNc. However the IFNc: IL-10 ratio positively correlated
with TST induration suggesting that the relationship between PPD induced IFNc and IL-10 in the peripheral blood may be
important in controlling TST reactivity. Collectively these data provide further insights into how the TST is regulated in early
life, and how a positive response might be interpreted.
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Introduction
The tuberculin skin test (TST) is used as a standard diagnostic
tool to assess for infection with Mycobacterium tuberculosis (M.tb).
Tuberculin purified protein derivative (PPD) is administered
intradermally and the induration measured 48 – 72 hours later.
It is generally accepted that in adults, a TST response $10 mm
induration is indicative of M.tb infection, however in children the
diagnostic ‘cut off’ is not so well defined.
There are a number of determinants that affect TST reactivity.
The number of tuberculin units (T.U.) injected and the type of
tuberculin can vary according to national guidelines [1]. Several
reports suggest BCG vaccination at birth can result in TST
reactivity $10 mm for 6 – 12 months [2,3]. A longitudinal study
in Taiwan of children vaccinated at birth suggested optimal ‘cut
offs’ for children younger than 7 years of age should be .10 mm,
with 21 mm being more appropriate for the first year of life [3].
Interestingly a TST induration between 5 and 10 mm can persist
for up to 25 years after BCG vaccination [4]. This effect on TST
reactivity is dependent on strain and dose of BCG used [5,6], the
method of vaccine administration [6], the time since vaccination
[7,8], the number of BCG vaccinations administered [9], the age,
weight and nutritional status of the individual at the time of
vaccination [8,10] and genetic factors [11].
The TST can also be affected by cross reactivity with non-
tuberculous mycobacteria (NTM) in the environment. A meta-
analysis reported that in Montreal only 0.1% of TST responses
$10 mm could be attributed to exposure to NTM compared to
2.3% in India where the prevalence of NTM is much greater [1].
Exposure to NTM has also been implicated in TST reactivity in
Gambian BCG naı ¨ve infants whereby 22% (6/27) had a TST
.5m ma t4 K months of age [12].
There is little evidence to demonstrate that reactivity to the
TST relates to protection against tuberculosis (TB), however
delayed-type hypersensitivity (DTH) to mycobacterial antigens is
associated with protection against leprosy [13]. Immune correlates
of TST have not been well defined and there are conflicting
reports on whether PPD induced peripheral blood responses
correlate with the TST, making it difficult to interpret the
diagnostic potential of the TST [12,14].
This study aimed to examine how environmental mycobacterial
exposure and BCG vaccination affect the TST in Gambian infants
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BCG vaccinated at birth to a group that were BCG naı ¨ve at 4K
months of age. Our results suggest that BCG vaccination is likely
to be responsible for TST reactivity at 4K months of age, and that
exposure to mycobacterial antigens in the environment had no
effect on TST reactivity at this age. We also investigated the
association between peripheral blood immune parameters and
TST reactivity. We found that PPD induced IFNc production in
the peripheral blood correlated with TST reactivity, but not with
TST induration, and the ratio of IFNc: IL-10 positively correlated
with the TST and therefore may be important in controlling TST
reactivity.
Methods
Study design
This study was approved by the Joint Gambia Government/
MRC Ethics Committee and the London School of Hygiene and
Tropical Medicine Ethics Committee as part of a larger
longitudinal study. Gambian newborns were recruited at delivery
from the Sukuta Hospital over a 2 year period. Following signed
informed consent of a parent/guardian, newborns were rando-
mised into one of two groups: Group 1 were vaccinated with BCG
(0.05 mL intradermally, Serum Institute of India Ltd, Russian
strain) at birth and Group 2 were vaccinated with BCG at 4K
months of age (Fig. 1). Exclusion criteria included low birth weight
(,2.5 kg); twin pregnancy; intercurrent infection; exposure to TB
at time of recruitment, or likelihood of moving location during the
study period. All other childhood vaccines were administered
according to the recommended Extended Programme on
Immunisation (EPI) schedule in The Gambia (Table S1). Subjects
were followed up in the first week of life, and then monthly to 9
months of age. Blood was collected at birth (50 mLs of cord blood)
and at 4K- and 9-months of age (5 mL venous blood) into
heparinised syringes (7.5 U/mL of blood) and transferred to the
laboratories within 6 hrs of collection. This study describes
immune responses related to TST reactivity at 4K months of
age; the more detailed longitudinal mycobacterial responses are
described elsewhere [15]. At each visit a TB questionnaire was
completed to assess for TB exposure. HIV status of the
participants was not assessed but an estimated sero-prevalence of
2–4% among adults and 0.1% amongst children (0 – 14 years of
age) in The Gambia [16] suggests that HIV was unlikely to be a
significant confounder in this study. Recent studies in The Gambia
have shown very low levels of helminth infection of between 0 –
3% in adult populations [17] suggesting helminth infection is also
unlikely to be a confounding factor in the study.
Tuberculin Skin Test (TST)
Reactivity to the TST was assessed at 4K and 20–28 months of
age in all subjects (Fig. 1). One dose of 0.1 mL of tuberculin PPD
RT23 (containing 0.04 mg (2 Tuberculin Units), Statens Serum
Institute (SSI), Denmark) was injected intradermally by a trained
clinician or fieldworker. The induration (average of length and
width) was measured 48 – 72 hours later and confirmed by a
trained clinician. A positive response was considered to be
$5 mm, and possible infection with M.tb if the TST was
$10 mm. Any subject or close contact with a confirmed case of
TB was referred to the TB clinic for further treatment. Infants
found to be exposed to TB prior to BCG vaccination in Group 2
were immediately dropped from the study and monitored closely
for TB disease.
Cell culture conditions
From each blood sample, 500 mL of whole blood was cultured
for 5 days with purified protein derivative of tuberculin (PPD,
25 mg/ml; SSI, Denmark), a positive control (Staphylococcal
enterotoxin B, SEB, 5 mg/ml; Sigma Aldrich, UK) and an
unstimulated negative control. After 24 hours in culture the whole
blood was diluted 1:5 with serum-free RPMI medium containing
2% penicillin/streptomycin (10,000 U/mL) and 1% L-glutamine,
since optimization assays and previous studies [18] indicated better
survival of cells in diluted blood. After 5 days of culture 100 mLo f
supernatant was collected and stored at 220uC to quantify the
production of cytokines, and the remaining cells were phenotyped
by flow cytometry.
T cell Phenotyping
T cells were phenotyped according to manufacturer’s instruc-
tions, fixed in 150 mL fix buffer (2% formalin in PBS) and
processed on the 4 parameter BD FACS Calibur
TM flow
cytometer using the following antibodies: CD4 PE (SK3), CD4
APC (SK3), CD8 PerCP (SK1), CD25 FITC (M-A251), IL-10 PE
(RM4-5), Ki-67 FITC (B56/MOPC-21) (BD Pharmingen, France)
and FOXP3 APC (PCH101) (e-Bioscience, US). Antibody
titrations and isotype controls were previously optimised in
preliminary assays. Flow cytometric data was analysed using a
template previously created during optimisations in Flow Jo
Figure 1. BCG vaccine schedule of study subjects. Babies were recruited at birth and randomised into either Group 1 (vaccinated at birth) or
Group 2 (vaccinated at 4K months of age) and followed up for 9 months. For all subjects a blood sample was collected at birth (50 mL cord blood),
4K- and 9- months of age (5 mL). A tuberculin skin test (TST) was performed at 4K and at 20 – 28 months of age. Each child was followed up
monthly for 9 months and then again at 20–28 months of age with a TB questionnaire (TBQ) and a general health questionnaire.
doi:10.1371/journal.pone.0012287.g001
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as illustrated in Fig. S1, with minor sample specific modifications
between experiments.
Cytometric bead array
Supernatants were spun at 1500 rpm for 2 mins to pellet any
precipitation in the sample. All samples stimulated with SEB were
diluted 1:2 with media containing 10% serum. A 6-plex system
containing antibodies to IFNa ˜, IL-10, IL-13, IL-6 and IL-17 (Th1
cytokine kit, Bio-Rad, California, US) was used to determine
cytokine production using 50 mL of supernatant. The bead array
assays were performed using 50 mL of sample according to
manufacturer’s instructions (Bio-Rad) and measured using the Bio-
Plex 200 Suspension Array system (Bio-Rad). Standard curve
outliers were eliminated by identifying samples where the
coefficient of variance (%CV).10% and observed/expected x
100 (obs/exp*100) was outside the range of 100
+/2 20. Cytokine
concentrations below the level of detection were calculated as zero
in the analysis. All values that were greater than the highest range
within the standard curve were repeated after further dilutions
with media containing 10% human AB serum.
Data collection and verification
Data points/samples were eliminated if any of the following
problems arose: EPI vaccine administered less than 7 days prior to
blood collection, cultures were contaminated, antibody staining
was inadequate, the positive control (SEB) did not induce a
response in vitro and acquisition of less than 1,000 lymphocytes.
These issues occurred for approximately 10% of the .500 panels
analysed, with 7% being due to a low number of lymphocytes,
most frequently for the cord blood samples.
Statistical analysis
For most values the data was not normally distributed and
therefore non-parametric tests were used throughout. Cross
sectional comparisons between groups were assessed using a 2-
sided Mann-Whitney U test at 95% significance. * p=0.009 –
0.050, ** p=0.001 – 0.010, *** p,0.001. Correlations were
analysed using Spearmans correlation coefficient. Bonferroni
corrections were made according to the numbers of parameters
assessed and the number of times a dataset was analysed. Data was
analysed using R version 2.9.2 (The R Foundation, official part of
the FSF’s GNU project) and GraphPad Prism 5.01 (GraphPad
Software Inc., US).
Results
Cohort Characteristics
103 neonates were recruited into the study at birth; 53 were
randomised into Group 1 (vaccinated at birth) and 50 were
randomised into Group 2 (vaccinated at 4K months of age).
Ninety infants were followed up at 4K months (87.3%) and 85 at
20–28 months (82.5%). Details of this cohort are described
elsewhere [15]; overall this study cohort was representative of the
local Sukuta community [19].
TST reactivity
At 4K months of age all children received a TST. All BCG
naı ¨ve subjects (Group 2) lacked reactivity to the TST (Fig. 2A).
Among the BCG vaccinated group, 47% (24/51) of subjects
exhibited a positive response ($5 mm, responders or R) and the
remaining 53% were non-responders (NR). Among the respond-
ers, 58% (14/24) had responses $10 mm and were therefore
investigated for possible M.tb infection (Fig. 2A) but TB was not
diagnosed in any of these individuals.
A repeat Mantoux test was undertaken on all subjects at 20 – 28
months of age. At this age all children had been vaccinated with
BCG either at birth or at 4K months of age. Only 10/85 (11.8%)
children had a positive TST ($5 mm) and 72/85 (84%) did not
react to the TST at this later age. When comparing the TST
results at 4K and 20–28 months of age, it was clear that the timing
of the BCG vaccination did not affect the TST at this later age,
with similar numbers of positive subjects in both groups (Group 1:
n=5; Group 2: n=5, p=0.8868) (Fig. 2B). Four individuals had a
response of $10 mm and were followed up for possible M.tb
infection, but TB was not diagnosed in any of these individuals.
BCG scar at 20 – 28 months of age
The presence and size of the BCG scar was recorded at the 20 –
28 month visit and was found in 91.8% of individuals with a
Figure 2. Tuberculin Skin Test (TST) and BCG scar results. Two T.U. PPD were injected into the forearm of each individual. The average length
x width (mm) of the induration was measured 48 – 72 hours later at (A) 4K months of age (Group 1, n=51, Group 2, n=39) and (B) 20– 28 months of
age (Group1, n=45, Group 2, n=40). The black line represents a 5 mm ‘cut off’ for positive reactivity. (C) The relationship between scar and gender
(male n=42, female n=43). Group 1 - vaccinated at birth, Group 2 - vaccinated at 4K months of age.
doi:10.1371/journal.pone.0012287.g002
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children failed to develop a scar to BCG vaccination but reactivity
to the TST was present in 30% of these (Table 1) suggesting that a
lack of BCG scar was unlikely to be due to incorrect
administration of the BCG vaccine. There was no relationship
between lack of BCG scar and timing of BCG vaccination (4
children in Group 1 and 3 children in Group 2 failed to produce a
scar).
There has been increasing interest in the role of gender in
responses to vaccines [20], however there was no significant
relationship between sex and reactivity to the TST at 4K months
of age (Fisher’s Exact test p=0.580) (Table 2). In addition,
scarring after BCG vaccination was also not related to sex (data
not shown) however, the median scar size was significantly larger
in males (4 mm) than females (3 mm) (Fig. 2C) which has been
shown previously in Malawian studies [21].
At 4K months of age TST responders induce greater
IFNc production than non-responders in the peripheral
blood
The TST is caused by a localised delayed-type hypersensitivity
(DTH) to PPD at the site of injection, but it remains unclear as to
how TST reactivity relates to PPD responses in peripheral blood.
At 4K months of age the responders (R) within the BCG
vaccinated group had higher in vitro IFNc reactivity to PPD in
peripheral blood than the non-responders (NR) (Fig. 3A).
Interestingly, the NR in the vaccinated group, most of whom
had an induration of zero, still exhibited greater IFNc reactivity
than the BCG naı ¨ve individuals from Group 2 that also had no
reaction to the TST (Fig. 3A). Although R produced more IFNc
compared to NR, there was no correlation between the
concentration of IFNc produced and the size of induration of
the TST reaction in R (r=0.2317, p=0.2875) (Fig. 3A). There
was a borderline higher IL-6 production to PPD in responders
(PPD; p=0.0560) although this association was lost after
correcting for multiple testing and did not correlate with TST
induration. IL-13 and IL-17 were not significantly different
between R and NR (IL-13 p=0.6289 and IL-17 p=0.7584)
although they were significantly upregulated with BCG vaccina-
tion compared to the BCG naı ¨ve group at 4K months of age (IL-
13 p,0.0001, IL-17 p,0.0001, data not shown).
IL-10 production in peripheral blood is inversely related
to TST induration
At 4K months of age IL-10 production in PPD culture
supernatants was comparable between R and NR in the BCG
vaccinated group (p=0.9650, Fig. 3B). However, in those that
responded to the TST, the quantity of IL-10 inversely correlated
with the induration (r=20.4396, p=0.0358) (Fig. 3B). It was
noticeable that the greater concentrations of IL-10 were in Group
2, although this was not significant when applying the Fisher’s
exact test or the Chi-square test for trend. Conversely, 83% of the
individuals that downregulated IL-10 production (PPD stimulated
IL-10 levels were lower than the unstimulated background) were
TST responders, and this was significant using the Chi-square test
for trend (p=0.0485). BCG vaccinated infants had higher IFNc:
IL-10 ratios compared to unvaccinated infants (p,0.0001), but
there was no significant difference between the R and NR
(Fig. 3C). However there was a significant positive correlation
between the IFNc: IL-10 ratio and TST induration (Fig. 3C).
CD4
+ and CD8
+ T cell production of IL-10 (by ICS) in
response to PPD did not differ between R and NR in Group 1, or
Group 1 (R or NR) compared to Group 2 (data not shown).
Furthermore, ICS IL-10 production did not correlate with TST
induration, suggesting a non-T cell source for the IL-10 that
correlates with TST induration.
Lack of correlation between frequencies of nTregs and
reactivity to the TST
Although IFNc production in PPD cultures was greater in the R
than the NR in group 1, activated T cells (CD4
+CD25
+) and
naturally occurring Tregs (nTregs, CD4
+CD25
+FOXP3
+) were
comparable (Fig. 4A and B) suggesting that the TST reactivity is
not related to these T cell populations. Similarly there was no
relationship between TST and proliferating T cell frequencies
(CD4
+ Ki-67
+ and CD8
+ Ki-67
+) (data not shown) in PPD cultures
compared to the NR, although for all groups the frequencies were
greater than the unvaccinated group (Fig. 4A and B).
Discussion
TST reactivity in 4K month old Gambian infants was found to
be induced by BCG vaccination at birth. BCG naı ¨ve individuals
responded to PPD in vitro suggesting mycobacterial exposure and
priming, but lacked TST reactivity suggesting that the environ-
mental mycobacterial exposure did not affect TST reactivity.
Investigation of the immune correlates of TST reactivity in
peripheral blood revealed greater IFNc production in the TST
responders but the absolute concentration of IFNc did not correlate
with induration. This discordance between IFNc and TST
Table 1. TST results and BCG scar formation at 20 – 28 months of age.
TST at 20–28 months of age (mm) Number of individuals (% of total) Number of individuals with scar (% within TST category)
0 72 (84.7) 67 (93.1)
1 – 4.5 3 (3.5) 2 (66.7)
5 – 9.9 6 (7.1) 5 (83.3)
$10 4 (4.7) 4 (100)
doi:10.1371/journal.pone.0012287.t001
Table 2. The relationship between TST reactivity and gender
at 4K months of age.
Female (n) Male (n)
Group 1 R 12 12
Group 1 NR 16 11
Group 2 NR 19 20
R=responders $5m m
NR=non responders,5m m
doi:10.1371/journal.pone.0012287.t002
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induration may be regulated by different factors. In support of this
hypothesis Martins et al found strong erythema to the TST without
induration which correlated with an increased IFNc response to
PPD [14]. IL-10 has been shown to decrease DTH in mice and
strongly decrease expression of the skin homing receptor, cutaneous
lymphocyte-associated antigen (CLA) on T cells [22,23]. Our study
found an inverse correlation between IL-10 and TST induration
and a positive correlation between the ratio of IFNc: IL-10 and
TST reactivity suggesting IL-10 may contribute to regulating the
size of the TST reaction. It would be interesting to examine the
expression of CLA by T cells in the future in relation to TST
reactivity. Regulatory T cells have also been implicated as another
factor that controls delayed type hypersensitivity. Studies that have
examined nickel allergy have found that functional Tregs reduce
skin reactivity [24], however our results show no differences in the
frequencies of nTregs between R and NR although Treg function
was not examined. It is also worth noting that genetic factors may
also contribute to how individuals respond to the TST [11,25] but
this was not examined in this study.
The in vitro studies showed strong PPD responses in the
peripheral blood of the BCG naı ¨ve infants at 4K months, possibly
due to NTM exposure. However, none of these individuals reacted
to the skin test at this age suggesting that environmental
mycobacterial exposure does not affect the TST response at this
age. This may be related to the mycobacterial dose or lack of cross
reactivity between specific mycobacterial antigens in the environ-
ment and tuberculin PPD. Another explanation would be that the
skin test is less sensitive than in vitro whole blood assays at detecting
mycobacterial immunity. However previous work in The Gambia
showed TST reactivity ($5 mm) in 22% (6/27) of BCG naı ¨ve
children at 4K months of age [12]. Corrah et al has shown that
prevalent NTM species differ between geographical locations
within in The Gambia which could provide an explanation for this
discrepancy between our findings and this latter study [26].
Not all individuals in the BCG vaccinated group responded to the
TST, in fact 53% of these infants lacked any response to the TST
(i.e. 0 mminduration). The possibility of false negative responses was
considered. It has been shown that age (both the very young and the
very old) can be responsible for false negative TST reactivity [27,28]
but other causes of false negative results include immunosuppression
[29], overwhelming TB infection [30], other viral [29,31] or
bacterial infections [32] and recent viral vaccinations [33,34]. In
our study the TST and blood collection were only performed on
Figure 3. Relationship between TST and cytokine production. At 4K months of age, whole blood was incubated with PPD for 5 days. (A)
IFNc and (B) IL-10 cytokine production and (C) the ratio of IFNc: IL-10 was measured in the supernatants of the PPD cultures (left). Unstimulated
control was subtracted from the PPD stimulated values, black bar represents the median value. A Mann-Whitney U test at 5% significance was applied
to compare the cytokine production between groups (left graphs). Correlation between the TST induration of the responders and IFNc, IL-10 and the
ratio of IFNc: IL-10 was calculated using Spearmans correlation coefficient at 5% significance (right graphs), dark grey line represents line of
regression. R=responder n=23, NR=non responder n=22, unvaccinated n=38.
doi:10.1371/journal.pone.0012287.g003
Figure 4. Relationship between TST and T cell phenotype in response to PPD. At 4K months of age, whole blood was cultured with PPD
for 5 days. (A) frequencies of activated T cells (CD4
+CD25
+) and (B) naturally occurring Tregs (CD4
+CD25
+FOXP3
+) were measured with respect to TST
reactivity. Unstimulated control was subtracted from the PPD stimulated values, black bar represents the median value. Comparisons between
responders (R), non responders (NR) and unvaccinated individuals were calculated using a Mann-Whitney U test at 5% significance. R=responder
n=22, NR=non responder n=21, unvaccinated n=34.
doi:10.1371/journal.pone.0012287.g004
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Gambia suggesting the lack of TST reactivity observed in some
individuals was not due to false negative responses.
The diagnostic use of the TST may be improved by modifying
the ‘cut off’ values used to detect M.tb infection. Studies by Chan
et al suggested that the ‘cut off’ in infants up to 1 year of age should
be 21 mm, and that anything below this can be attributed to BCG
vaccination [3]. Our study would support this as no child with
TST reactivity .10 mm had any signs of M.tb infection or
exposure to TB. By 20 months of age Chan proposed a ‘cut off’ of
18 mm in those vaccinated with BCG at birth [3]. Indeed 99% of
children in our study had a TST,18 mm induration. Our data
therefore supports using these higher ‘cut offs’ for suspected M.tb
infection in young BCG vaccinated infants but future studies
would be needed to verify this.
Overall our results showed that recent BCG vaccination
affected TST reactivity in young infants but by 20 months of
age the BCG vaccine had much less effect on the TST response.
At 4K months of age TST reactivity only occurred in the BCG
vaccinated group, and those with responses .10 mm had no
evidence of M.tb infection supporting the use of higher ‘cut offs’ for
diagnosing M.tb infection or TB disease in this age group.
Although the BCG naı ¨ve individuals did not react to the TST they
responded to PPD in vitro, suggesting that environmental
mycobacterial exposure did not prime a TST in this age group.
Finally examining the immune correlates that relate to TST
reactivity suggested that IFNc correlated with TST reactivity but
IL-10 inversely correlated with TST induration suggesting
separate factors may be involved in controlling the TST reaction.
These data therefore shed more light on how to interpret TST
responses in young children who receive BCG vaccine early and
are exposed to mycobacteria in the environment.
Supporting Information
Table S1 Extended Programme of Immunisation (EPI) vaccine
schedule in The Gambia (2006 – 2009). Apart from the changes in
the BCG vaccine schedule illustrated in Figure 1, all other vaccines
were administered according to the Extended Programme of
Immunisation (EPI) in The Gambia.
Found at: doi:10.1371/journal.pone.0012287.s001 (0.07 MB
DOC)
Figure S1 Representative flow cytometry plots of PPD stimu-
lated whole blood. 500 mL whole blood was cultured with PPD for
5 days. BCG vaccinated subjects (A and C) and unvaccinated (B
and D) illustrating % CD25
+ T cells gated on CD4
+ T cells (A and
B) and % CD25
+FOXP3
+ T cells gated on CD4
+ T cells (C and D)
(unstimulated samples on the left and PPD stimulated samples on
the right).
Found at: doi:10.1371/journal.pone.0012287.s002 (4.67 MB
TIF)
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